

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**廣州藥業股份有限公司**

**Guangzhou Pharmaceutical Company Limited**

*(a joint stock company with limited liability established in the People's Republic of China)*  
(H Share Stock Code: 0874)

## OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Reference is made to the announcement of Guangzhou Pharmaceutical Company Limited (the “Company”) dated 7 November 2011 in relation to a proposed major assets reorganization (the “Event”) involving the Company as published in the Shanghai Securities News, the Securities Times and on the website of The Shanghai Stock Exchange ([www.sse.com.cn](http://www.sse.com.cn)) and the content of which has also been reproduced and published as an overseas regulatory announcement on the website of The Stock Exchange of Hong Kong Limited.

As at the date of this announcement, the relevant parties involving in the Event are consulting the relevant authorities on the Event. As there are uncertainties about the Event, the Company has continued to suspend the trading in the shares of the Company in order to secure the interests of investors.

During the period of suspension in the dealing of its shares, the Company will fulfill its disclosure obligations in respect of the progress of the Event on a timely basis, and make further announcements regarding the progress of the Event every five trading days.

The Board of  
**Guangzhou Pharmaceutical Company Limited**

Guangzhou, the PRC, 11 November 2011

*As at the date of this announcement, the Board comprises Mr. Yang Rongming, Mr. Li Chuyuan, Mr. Shi Shaobin and Mr. Wu Changhai as executive directors, and Mr. Liu Jinxiang, Mr. Li Shanmin, Mr. Zhang Yonghua, Mr. Wong Lung Tak Patrick and Mr. Qiu Hongzhong as independent non-executive directors.*